A detailed history of Vanguard Group Inc transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,989,693 shares of TARS stock, worth $94.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,989,693
Previous 1,826,632 8.93%
Holding current value
$94.1 Million
Previous $66.4 Million 18.55%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$25.17 - $38.73 $4.1 Million - $6.32 Million
163,061 Added 8.93%
1,989,693 $54.1 Million
Q1 2024

May 10, 2024

BUY
$19.61 - $39.22 $4.53 Million - $9.06 Million
231,131 Added 14.49%
1,826,632 $66.4 Million
Q4 2023

Feb 14, 2024

BUY
$12.98 - $20.73 $567,213 - $905,880
43,699 Added 2.82%
1,595,501 $32.3 Million
Q3 2023

Nov 14, 2023

BUY
$14.75 - $24.62 $4.66 Million - $7.78 Million
316,128 Added 25.58%
1,551,802 $27.6 Million
Q2 2023

Aug 14, 2023

BUY
$11.57 - $19.63 $117,238 - $198,910
10,133 Added 0.83%
1,235,674 $22.3 Million
Q1 2023

May 15, 2023

BUY
$11.92 - $16.27 $155,806 - $212,665
13,071 Added 1.08%
1,225,541 $15.4 Million
Q4 2022

Feb 10, 2023

BUY
$14.12 - $18.72 $3.91 Million - $5.18 Million
276,821 Added 29.59%
1,212,470 $17.8 Million
Q3 2022

Nov 14, 2022

BUY
$14.08 - $18.5 $3.94 Million - $5.18 Million
279,826 Added 42.67%
935,649 $16 Million
Q2 2022

Aug 12, 2022

BUY
$11.08 - $19.08 $2.18 Million - $3.76 Million
197,007 Added 42.94%
655,823 $9.58 Million
Q1 2022

May 13, 2022

SELL
$14.49 - $24.28 $5,419 - $9,080
-374 Reduced 0.08%
458,816 $7.72 Million
Q4 2021

Feb 14, 2022

BUY
$21.21 - $29.68 $640,542 - $896,336
30,200 Added 7.04%
459,190 $10.3 Million
Q3 2021

Nov 12, 2021

BUY
$21.45 - $29.22 $63,170 - $86,052
2,945 Added 0.69%
428,990 $9.25 Million
Q2 2021

Aug 13, 2021

BUY
$27.16 - $38.59 $11.6 Million - $16.4 Million
426,045 New
426,045 $12.3 Million

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.26B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.